Evaluation of the in-vitro Antifungal Activity of Selected Fungal Species Tested Against Opportunistic Human Pathogen Candida albicans

Abstract

Candida albicans is currently the fourth-leading cause of hospital-acquired bloodstream infections, reaching a mortality rate of up to 35–40% for systemic or disseminated infections. Systemic mycoses can occur in patients with severely impaired immune systems (AIDS), with organ or bone marrow transplants, cancer patients undergoing chemotherapy, and patients in ICU (neonates and elderly). It is, therefore, obvious that there is a substantial need for fast, effective antifungal antibiotics to combat fungal infections. The present investigation has been proposed to screen effective fungal metabolites for the control of Candida albicans by evaluating the potential of fungal bioactive compounds, its purification and characterization